{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:07:23Z","timestamp":1793848043353,"version":"4.6.1"},"reference-count":25,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"8","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>Histone deacetylase (HDAC) inhibition downregulates hypoxia-inducible factor-1\u03b1 and modulates multiple metabolomic pathways relevant in cancer. Here we report a potential novel biomarker to predict exceptional responders (&gt;3 years) in patients receiving HDAC and vascular endothelial growth factor (VEGF) inhibition.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PATIENTS AND METHODS<\/jats:title>\n            <jats:p>Patients with solid tumor malignancies were enrolled in this phase Ib trial of abexinostat (4\/7 \u00d721 days) and pazopanib (28\/28 days), with a dose expansion in renal cell carcinoma (RCC). Plasma was analyzed for metabolomics and peripheral blood mononuclear cells (PBMCs) for VEGF and HDAC2 expression levels.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>\n              Fifty-one patients were enrolled: n = 36 patients in dose escalation and n = 15 in dose expansion. After the initial report in 2017, six patients had remained on study: four with RCC and one each with medullary thyroid and thymic neuroendocrine carcinoma. One patient with RCC remains on treatment for &gt;11 years after progression on five systemic therapies. Overall, the median duration of therapy measured 5.6 (1-133) months. The median duration of therapy in exceptional responders measured 44.1 (39.8-133+) months. The median overall survival in patients with high PBMC HDAC2 expression versus low HDAC2 was 32.3 versus 9.2 months (\n              <jats:italic>P<\/jats:italic>\n              = .004) for all patients and 43.3 versus 25.1 months for patients with RCC (\n              <jats:italic>P<\/jats:italic>\n              = .09). Exceptional responders had lower kynurenine levels both pre- and post-treatment (\n              <jats:italic>P<\/jats:italic>\n              = .002,\n              <jats:italic>P<\/jats:italic>\n              &lt; .001, respectively). HDAC2 and kynurenine expression levels were inversely correlated (\n              <jats:italic>P<\/jats:italic>\n              = .02).\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Abexinostat added to pazopanib shows extended tolerability and long-term responses and survival. PBMC HDAC2 levels, the abexinostat target, are relevant predictors of response. In addition, metabolomic assessment points to kynurenine as a predictor for exceptional response to combined VEGF plus HDAC inhibition.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/po.24.00328","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T20:59:29Z","timestamp":1731013169000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":4,"title":["Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2317-2721","authenticated-orcid":true,"given":"Erica S.","family":"Tsang","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA"},{"name":"Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7003-7982","authenticated-orcid":true,"given":"Rahul R.","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily K.","family":"Bergsland","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Calabrese","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandrine","family":"Rozie","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibapriya","family":"Chaudhuri","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallika S.","family":"Dhawan","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nela","family":"Pawlowska","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4871-0741","authenticated-orcid":true,"given":"Jennifer","family":"Grabowsky","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Thomas","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2074-0984","authenticated-orcid":true,"given":"Pamela N.","family":"Munster","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.10.088"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.01.021"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510016"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61613-9"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.63"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2008.11.012"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M406320200"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-013-2996-2"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.28163"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/207420"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.5350"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-015-0206-x"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0874-y"},{"key":"e_1_3_7_16_2","unstructured":"Metabolon. www.metabolon.com"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22422"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature12222"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-0890"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature10491"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm934"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.4161\/onci.19071"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M708192200"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20051110"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-284711"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.02.011"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO.24.00328","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T20:59:35Z","timestamp":1731013175000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO.24.00328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1200\/PO.24.00328"],"URL":"https:\/\/doi.org\/10.1200\/po.24.00328","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"2024-05-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2400328"}}